Authors reply [Matters arising]
Identifieur interne : 000825 ( Istex/Corpus ); précédent : 000824; suivant : 000826Authors reply [Matters arising]
Auteurs :Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2003-05.
English descriptors
- KwdEn :
- Teeft :
- Annual meeting, Antirheumatic drugs, Arthritis, Assoc physicians india, Clinical usage, Combination therapies, Corticosteroid, Corticosteroid treatment, Dmards, Early diagnosis, Email, Eular, Finland, Glucocorticoid, Glucocorticoid therapy, Isoniazid prophylaxis, Methotrexate, Organising secretariat, Osteoarthritis, Practical progress, Rapid rise, Rheum, Rheumatic diseases, Rheumatoid arthritis, Rheumatology, Sarcoidosis, Systemic lupus erythematosus, Website.
Url:
DOI: 10.1136/ard.62.5.494-a
Links to Exploration step
ISTEX:B6C29368E075B441247CE395F461AE4D1B2E4E59Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Authors reply [Matters arising]</title></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:B6C29368E075B441247CE395F461AE4D1B2E4E59</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1136/ard.62.5.494-a</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-6DLN482F-J/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000825</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000825</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Authors reply [Matters arising]</title></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2003-05">2003-05</date><biblScope unit="volume">62</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="494">494</biblScope></imprint><idno type="ISSN">0003-4967</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>disease modifying antirheumatic drugs</term><term>methotrexate</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Annual meeting</term><term>Antirheumatic drugs</term><term>Arthritis</term><term>Assoc physicians india</term><term>Clinical usage</term><term>Combination therapies</term><term>Corticosteroid</term><term>Corticosteroid treatment</term><term>Dmards</term><term>Early diagnosis</term><term>Email</term><term>Eular</term><term>Finland</term><term>Glucocorticoid</term><term>Glucocorticoid therapy</term><term>Isoniazid prophylaxis</term><term>Methotrexate</term><term>Organising secretariat</term><term>Osteoarthritis</term><term>Practical progress</term><term>Rapid rise</term><term>Rheum</term><term>Rheumatic diseases</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Sarcoidosis</term><term>Systemic lupus erythematosus</term><term>Website</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader></TEI><istex><corpusName>bmj</corpusName><keywords><teeft><json:string>glucocorticoid</json:string><json:string>corticosteroid</json:string><json:string>dmards</json:string><json:string>rheumatology</json:string><json:string>email</json:string><json:string>sarcoidosis</json:string><json:string>methotrexate</json:string><json:string>eular</json:string><json:string>osteoarthritis</json:string><json:string>website</json:string><json:string>rheumatoid arthritis</json:string><json:string>systemic lupus erythematosus</json:string><json:string>annual meeting</json:string><json:string>rheum</json:string><json:string>antirheumatic drugs</json:string><json:string>rheumatic diseases</json:string><json:string>finland</json:string><json:string>corticosteroid treatment</json:string><json:string>isoniazid prophylaxis</json:string><json:string>assoc physicians india</json:string><json:string>practical progress</json:string><json:string>glucocorticoid therapy</json:string><json:string>clinical usage</json:string><json:string>rapid rise</json:string><json:string>organising secretariat</json:string><json:string>combination therapies</json:string><json:string>early diagnosis</json:string><json:string>arthritis</json:string></teeft></keywords><subject><json:item><lang><json:string>eng</json:string></lang><value>methotrexate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>disease modifying antirheumatic drugs</value></json:item></subject><arkIstex>ark:/67375/NVC-6DLN482F-J</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>other</json:string></originalGenre><qualityIndicators><score>4.719</score><pdfWordCount>2707</pdfWordCount><pdfCharCount>19229</pdfCharCount><pdfVersion>1.1</pdfVersion><pdfPageCount>3</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>1</abstractWordCount><abstractCharCount>0</abstractCharCount><keywordCount>2</keywordCount></qualityIndicators><title>Authors reply [Matters arising]</title><genre><json:string>other</json:string></genre><host><title>Annals of the Rheumatic Diseases</title><language><json:string>unknown</json:string></language><issn><json:string>0003-4967</json:string></issn><eissn><json:string>1468-2060</json:string></eissn><volume>62</volume><issue>5</issue><pages><first>494</first></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>2003-05-01</json:string><json:string>1941</json:string><json:string>1997</json:string><json:string>2001</json:string><json:string>2001, 4325</json:string><json:string>1996</json:string></date><geogName></geogName><orgName><json:string>Rheumatism Foundation Hospital, FIN</json:string><json:string>Kaarela Rheumatism Foundation Hospital, Heinola, Finland Correspondence</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName></persName><placeName><json:string>Finland</json:string><json:string>Helsinki</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Aletaha et al</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/NVC-6DLN482F-J</json:string></ark><publicationDate>2003</publicationDate><copyrightDate>2003</copyrightDate><doi><json:string>10.1136/ard.62.5.494-a</json:string></doi><id>B6C29368E075B441247CE395F461AE4D1B2E4E59</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-6DLN482F-J/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-6DLN482F-J/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/NVC-6DLN482F-J/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Authors reply [Matters arising]</title><respStmt><resp>Références bibliographiques récupérées via GROBID</resp><name resp="ISTEX-API">ISTEX-API (INIST-CNRS)</name></respStmt></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://publisher-list.data.istex.fr">BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><availability><licence><p>Copyright 2003 by Annals of the Rheumatic Diseases</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</p></availability><date>2003-05-01</date></publicationStmt><notesStmt><note type="other" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Authors reply [Matters arising]</title><idno type="istex">B6C29368E075B441247CE395F461AE4D1B2E4E59</idno><idno type="ark">ark:/67375/NVC-6DLN482F-J</idno><idno type="DOI">10.1136/ard.62.5.494-a</idno><idno type="href">annrheumdis-62-494-2.pdf</idno><idno type="local">0620494a</idno></analytic><monogr><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="pISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><idno type="PublisherID-hwp">annrheumdis</idno><idno type="PublisherID-nlm-ta">Ann Rheum Dis</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2003-05"></date><biblScope unit="volume">62</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="494">494</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2003-05-01</date></creation><langUsage><language ident="en">en</language></langUsage><textClass xml:lang="en"><keywords scheme="keyword"><list><head>KWD</head><item><term>methotrexate</term></item><item><term>disease modifying antirheumatic drugs</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-05-01">Created</change><change when="2003-05">Published</change><change xml:id="refBibs-istex" who="#ISTEX-API" when="2017-10-17">References added</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-6DLN482F-J/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus bmj, element response not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="no"</istex:xmlDeclaration><istex:docType PUBLIC="-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" URI="archivearticle.dtd" name="istex:docType"></istex:docType><istex:document><article xml:lang="en" article-type="other"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="other">0620494a</article-id><article-id pub-id-type="other">annrheumdis;62/5/494-a</article-id><article-id pub-id-type="doi">10.1136/ard.62.5.494-a</article-id><article-id pub-id-type="other">494.2</article-id><article-id pub-id-type="other">ard.62.5.494-a</article-id><article-categories><subj-group subj-group-type="heading"><subject>Matters arising</subject></subj-group></article-categories><title-group><article-title>Authors reply</article-title></title-group><pub-date pub-type="ppub"><month>5</month><year>2003</year></pub-date><pub-date pub-type="epub"><day>1</day><month>5</month><year>2003</year></pub-date><volume>62</volume><volume-id pub-id-type="other">62</volume-id><volume-id pub-id-type="other">62</volume-id><issue>5</issue><issue-id pub-id-type="other">annrheumdis;62/5</issue-id><issue-id pub-id-type="other">5</issue-id><issue-id pub-id-type="other">62/5</issue-id><fpage seq="2">494</fpage><permissions><copyright-statement>Copyright 2003 by Annals of the Rheumatic Diseases</copyright-statement><copyright-year>2003</copyright-year></permissions><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-62-494-2.pdf"></self-uri></article-meta></front><response response-type="hwp-legacy-response" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-title>Annals of the Rheumatic Diseases</journal-title><abbrev-journal-title abbrev-type="publisher">Ann Rheum Dis</abbrev-journal-title><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="other">response1</article-id><title-group><article-title>Authors’ reply</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aletaha</surname><given-names>D</given-names></name><xref rid="AFF1"></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Smolen</surname><given-names>J</given-names></name><xref rid="AFF1"></xref></contrib><aff id="AFF1">Department of Rheumatology, University of Vienna, Austria</aff></contrib-group><pub-date pub-type="ppub"><month>5</month><year>2003</year></pub-date><pub-date pub-type="epub"><day>1</day><month>5</month><year>2003</year></pub-date><self-uri content-type="pdf" xlink:role="full-text" xlink:href="annrheumdis-62-494-2.pdf"></self-uri><kwd-group kwd-group-type="KWD" xml:lang="en"><kwd>methotrexate</kwd><kwd>disease modifying antirheumatic drugs</kwd></kwd-group></article-meta></front><body><p>The Finnish data presented by Drs Klaukka and Kaarela, which confirm the trend that we saw in our patient populations<xref rid="R1"><sup>1</sup></xref> as well as in the survey of rheumatologists,<xref rid="R2"><sup>2</sup></xref> are highly appreciated. They clearly show how drastically the use of disease modifying antirheumatic drugs (DMARDs) has changed over the past decade. Importantly, not only has the type of DMARDs employed most frequently undergone a change, but it appears from the table presented that the frequency of combination therapies may be quite high and that more patients receive DMARD treatment than even a few years ago. Such rapid changes are well in line with the observation we made in our matched surveys. There is another noteworthy aspect, which presumably also applies to the Finnish cohort: in our patients, median methotrexate doses increased from 10 mg (quartiles 7.5; 12.5 mg) in 1995 to 15 mg (10; 20 mg) in 2001, another indication that rheumatologists may be treating patients with rheumatoid arthritis (RA) much more efficiently today than less than a decade ago. This evolution is also supported by the effects of earlier DMARD use, as is also evident from our report.<xref rid="R2"><sup>2</sup></xref></p><p>Together with the new DMARDs, such as leflunomide, we have the tumour necrosis factor α and interleukin 1 blockers, whose appropriate dosing we also will have to learn over time. With more agents to come in the near future, we may soon be able to treat patients with RA in a way that previously we could only dream about.</p></body><back><ack><p>We would like to acknowledge that the reported work was performed in collaboration with the Ludwig Boltzmann Institute of Rheumatology and supported by a grant from the City of Vienna.</p></ack><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><citation xlink:type="simple"><bold>Aletaha D</bold>, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD therapies. <source>Rheumatology (Oxford)</source><year>2002</year>;<volume>41</volume>:<fpage>1367</fpage>–74.</citation></ref><ref id="R2"><label>2</label><citation xlink:type="simple"><bold>Aletaha D</bold>, Eberl G, Nell VPK, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. <source>Ann Rheum Dis</source><year>2002</year>;<volume>61</volume>:<fpage>630</fpage>–4.</citation></ref></ref-list></back></response></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Authors reply [Matters arising]</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Authors reply [Matters arising]</title></titleInfo><typeOfResource>text</typeOfResource><genre type="other" displayLabel="other" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-7474895G-0">other</genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><dateIssued encoding="w3cdtf">2003-05</dateIssued><dateCreated encoding="w3cdtf">2003-05-01</dateCreated><copyrightDate encoding="w3cdtf">2003</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><subject lang="en"><genre>KWD</genre><topic>methotrexate</topic><topic>disease modifying antirheumatic drugs</topic></subject><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>494</start></extent></part></relatedItem><relatedItem type="constituent" otherType="response"><titleInfo><title>Authors’ reply</title></titleInfo><name type="personal"><namePart type="given">D</namePart><namePart type="family">Aletaha</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Smolen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>hwp-legacy-response</genre><originInfo><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism. </publisher><dateIssued encoding="w3cdtf">2003-05</dateIssued></originInfo><relatedItem type="host"><titleInfo><title>Annals of the Rheumatic Diseases</title></titleInfo><titleInfo type="abbreviated"><title>Ann Rheum Dis</title></titleInfo><identifier type="ISSN">0003-4967</identifier><identifier type="eISSN">1468-2060</identifier><identifier type="PublisherID-hwp">annrheumdis</identifier><identifier type="PublisherID-nlm-ta">Ann Rheum Dis</identifier><part><date>2003</date></part></relatedItem><relatedItem type="isReferencedBy" displayLabel="R1"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><note>Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD therapies. Rheumatology (Oxford)2002;41:1367–74.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>41</number></detail><extent unit="pages"><start>1367</start></extent></part></relatedItem><relatedItem type="isReferencedBy" displayLabel="R2"><titleInfo><title>Ann Rheum Dis</title></titleInfo><note>Aletaha D, Eberl G, Nell VPK, Machold KP, Smolen JS. Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis2002;61:630–4.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>61</number></detail><extent unit="pages"><start>630</start></extent></part></relatedItem></relatedItem><identifier type="istex">B6C29368E075B441247CE395F461AE4D1B2E4E59</identifier><identifier type="ark">ark:/67375/NVC-6DLN482F-J</identifier><identifier type="DOI">10.1136/ard.62.5.494-a</identifier><identifier type="href">annrheumdis-62-494-2.pdf</identifier><identifier type="local">0620494a</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright 2003 by Annals of the Rheumatic Diseases</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-7M42M2QJ-2">bmj</recordContentSource><recordOrigin>Copyright 2003 by Annals of the Rheumatic Diseases</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/NVC-6DLN482F-J/record.json</uri></json:item></metadata><author></author><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000825 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000825 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:B6C29368E075B441247CE395F461AE4D1B2E4E59
|texte= Authors reply [Matters arising]
}}
| This area was generated with Dilib version V0.6.33. |  |